Literature DB >> 1445804

Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes.

R Halaban1, B Fan, J Ahn, Y Funasaka, H Gitay-Goren, G Neufeld.   

Abstract

Normal human melanocyte proliferation and differentiation is dependent on stimulation of one of three growth factor/receptor systems. They are fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and mast cell growth factor (MGF), which activate the FGF receptor, c-Met, and c-Kit, respectively, known to be receptor tyrosine kinases. In contrast, human melanoma cells from primary nodular and metastatic lesions grow autonomously partially because of inappropriate production of basic FGF (bFGF) and continuous activation of the bFGF-receptor kinase. Activation of transmembrane receptor tyrosine kinases in melanocytes stimulates not only proliferation but also the expression of pigmentation. Melanoma cells constitutively express several tyrosyl-phosphorylated proteins that in normal melanocytes are stimulated in response to growth factors. This high level of phosphorylation was not due to either the presence of constitutively active Kit kinase and Met kinase nor to the absence of any of several known protein tyrosine phosphatases. Because bFGF by itself does not transform melanocytes to melanomas, there must be additional cooperating factors that confer the malignant phenotype to pigment cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445804     DOI: 10.1097/00002371-199210000-00002

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  2 in total

1.  Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin.

Authors:  C Berking; R Takemoto; K Satyamoorthy; R Elenitsas; M Herlyn
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes.

Authors:  Joanne Soong; Glynis Scott
Journal:  J Cell Sci       Date:  2012-11-30       Impact factor: 5.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.